MannKind Corporation (Nasdaq and TASE: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients.
AFREZZA® (pronounced uh-FREZZ-uh), approved in 2014 by the U.S. Food and Drug Administration, is a rapid-acting inhaled insulin therapy indicated to improve glycemic control in adults with diabetes. Taken at the start of a meal using a specially designed inhaler, Afrezza dissolves rapidly upon inhalation to the deep lung and delivers insulin quickly to the bloodstream. Peak insulin levels are achieved within 12 to 15 minutes of use and help to control post-meal blood sugar spikes that affect HbA1C levels. More >
Matthew J. Pfeffer, CEO/CFO and Raymond W. Urbanski, CMO held an investor conference call on February 3 to update on company developments. To view the slide deck Click Here. To view related FAQs Click Here.
To view the FAQ: Technosphere® licensing agreement announced by MannKind™, January 21, 2016. Click Here